Cancer’s Grip May Be Loosened by Tampering with DNA Clamp

A rationally designed drug-like protein interferes with the protein-protein interactions of PCNA, the so-called DNA clamp, offering a new way of hindering DNA replication in fast-proliferating cancer cells.

Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and...

Through the acquisition, Otsuka will inherit Visterra’s Hierotope® platform, intended to design and engineer precision antibody-based therapies, and expand its pipeline with Visterra’s programs targeting infectious diseases, kidney diseases, cancer, and chronic pain.

Lyme, Seven Other Tick-Borne Diseases Detected with New Serochip

A serochip-based blood test with multiplex capabilities has been designed to detect Lyme disease and/or one of seven other tick-borne diseases

Antiviral Therapies Shown to Be Effective against Multiple Viruses

Team says research results show existing safe-in-human broad-spectrum antivirals could be used on other viral infections.

Vical Halts Development of HSV-2 Vaccine after Phase II Failure

The HSV-2 vaccine missed its primary endpoint in the Phase II study of annualized lesion recurrence rate

GE Healthcare, Swedish Government Open an Innovation Center in Uppsala

Testa Center focuses on advancing manufacturing capabilities and the commercialization of new technologies in life sciences, aligning with Sweden's goals of strengthening its capacity for innovation and thus its economic competitiveness.

Lilly, Dicerna Launch $3.7B+ RNAi Collaboration

Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10...

Novel RNA-based Vaccine Provides Protection Against Malaria

Researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites use to evade the immune system

Breast Cancer Immunotherapy Delivered without Side Effects

While cancer immunotherapy is one of the most exciting new research areas due to the potential it holds for treating tumors that have been...

FDA Approves First Smallpox-Indicated Treatment, SIGA’s TPOXX

With the approval, SIGA said, it is entitled to a $41 million payment under its a $472M contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), which joined SIGA in developing the treatment.